Shanghai Junshi Biosciences (HKG:1877) completed the sale of 41 million H shares in a transaction valued at around HK$1.04 billion, according to a Friday bourse filing.
Shares gained about 7% in Monday's afternoon trade.
The cancer medicine developer sold the shares at HK$25.35 apiece and proceed raised will be used to advance the development of its therapies, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.